BIOLASE First Quarter Sales Increase 102 Percent

Apr 05, 2001, 01:00 ET from BIOLASE Technology, Inc.

    SAN CLEMENTE, Calif., April 5 /PRNewswire/ -- BIOLASE Technology, Inc.
 (Nasdaq: BLTI), announced today that sales for the first quarter of 2001 were
 $3,082,692, an increase of 102 percent over the same period last year.
     Jeffrey W. Jones, BIOLASE president and CEO, stated, "The level of our
 sales continues to increase at a very strong pace both domestically and
 internationally.  Underlying this increase is the excellent reception by the
 dental community of our new Waterlase(TM), a laser that allows dentists to
 perform painless dental procedures, and the Twilite(TM), a laser for teeth
 whitening and soft tissue surgery.
     "Additionally, we are well positioned for another excellent quarter, and
 we are very optimistic about continued outstanding growth for the remainder of
 2001.  We also believe that our sales should not be adversely affected by the
 global economic slowdown.  Both the Waterlase and the Twilite are excellent
 tools for dentists to use to differentiate themselves in an increasingly
 competitive market.  Waterlase dentists position themselves as modern,
 advanced technology practices offering painless laser dentistry in place of
 the traditional needle, anesthesia and drill."
 
     BIOLASE Technology, Inc. (www.BIOLASE.com), is an advanced medical
 technology company, which possesses and develops advanced dental, cosmetic,
 aesthetic and surgical products, including Waterlase (HydroKinetic(R))
 surgical cutting systems and other advanced laser- and non-laser-based
 products for the professional and consumer markets.  The company's products
 incorporate patented and patent-pending technologies in the pursuit of
 painless surgery.  BIOLASE is the world leader in painless hard- and soft-
 tissue dental laser technology.
 
     The matters discussed in this news release include forward-looking
 statements which are subject to various risks, uncertainties and other factors
 that could cause actual results to differ materially from the results
 anticipated in such forward-looking statements.  Such risks, uncertainties and
 other factors include, but are not limited to, the effect of actions of third
 parties, including governmental officials, the timely development and
 acceptance of new products, the impact of competitive products and pricing,
 and other risks detailed from time to time in the Company's filings with the
 Securities and Exchange Commission, including the reports on Forms 10-K and
 10-Q.  These forward-looking statements represent the Company's judgment as of
 the date of this release.  The Company disclaims, however, any intent or
 obligation to update these forward-looking statements.
 
     For further information, please contact Lori Parks, VP-Editorial, Elisa
 Keys, SVP-Media Relations, or Leighton Foster, Investor Relations, of Porter,
 LeVay & Rose, Inc., 212-564-4700; or Jeffrey W. Jones, President and CEO of
 BIOLASE Technology, Inc., 949-361-1200.
 
 

SOURCE BIOLASE Technology, Inc.
    SAN CLEMENTE, Calif., April 5 /PRNewswire/ -- BIOLASE Technology, Inc.
 (Nasdaq: BLTI), announced today that sales for the first quarter of 2001 were
 $3,082,692, an increase of 102 percent over the same period last year.
     Jeffrey W. Jones, BIOLASE president and CEO, stated, "The level of our
 sales continues to increase at a very strong pace both domestically and
 internationally.  Underlying this increase is the excellent reception by the
 dental community of our new Waterlase(TM), a laser that allows dentists to
 perform painless dental procedures, and the Twilite(TM), a laser for teeth
 whitening and soft tissue surgery.
     "Additionally, we are well positioned for another excellent quarter, and
 we are very optimistic about continued outstanding growth for the remainder of
 2001.  We also believe that our sales should not be adversely affected by the
 global economic slowdown.  Both the Waterlase and the Twilite are excellent
 tools for dentists to use to differentiate themselves in an increasingly
 competitive market.  Waterlase dentists position themselves as modern,
 advanced technology practices offering painless laser dentistry in place of
 the traditional needle, anesthesia and drill."
 
     BIOLASE Technology, Inc. (www.BIOLASE.com), is an advanced medical
 technology company, which possesses and develops advanced dental, cosmetic,
 aesthetic and surgical products, including Waterlase (HydroKinetic(R))
 surgical cutting systems and other advanced laser- and non-laser-based
 products for the professional and consumer markets.  The company's products
 incorporate patented and patent-pending technologies in the pursuit of
 painless surgery.  BIOLASE is the world leader in painless hard- and soft-
 tissue dental laser technology.
 
     The matters discussed in this news release include forward-looking
 statements which are subject to various risks, uncertainties and other factors
 that could cause actual results to differ materially from the results
 anticipated in such forward-looking statements.  Such risks, uncertainties and
 other factors include, but are not limited to, the effect of actions of third
 parties, including governmental officials, the timely development and
 acceptance of new products, the impact of competitive products and pricing,
 and other risks detailed from time to time in the Company's filings with the
 Securities and Exchange Commission, including the reports on Forms 10-K and
 10-Q.  These forward-looking statements represent the Company's judgment as of
 the date of this release.  The Company disclaims, however, any intent or
 obligation to update these forward-looking statements.
 
     For further information, please contact Lori Parks, VP-Editorial, Elisa
 Keys, SVP-Media Relations, or Leighton Foster, Investor Relations, of Porter,
 LeVay & Rose, Inc., 212-564-4700; or Jeffrey W. Jones, President and CEO of
 BIOLASE Technology, Inc., 949-361-1200.
 
 SOURCE  BIOLASE Technology, Inc.